Skip to main content
SpringerLink
Log in

Ziprasidone: zealous in the treatment of schizophrenia and schizoaffective disorder

  • New Drugs and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Gunasekara NS, Spencer CM, Keating GM. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2002; 62 (8): 1217–51

    Article  PubMed  CAS  Google Scholar 

  2. Kelleher JP, Centorrino F, Albert MJ, et al. Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents. CNS Drugs 2002; 16 (4): 249–61

    Article  PubMed  CAS  Google Scholar 

  3. Keck Jr P, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 1998; 140: 173–84

    Article  PubMed  CAS  Google Scholar 

  4. Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 1999; 20: 491–505

    Article  PubMed  CAS  Google Scholar 

  5. Goff DC, Posever T, Herz L, et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1998; 18: 296–304

    Article  PubMed  CAS  Google Scholar 

  6. Simpson G, Romano S, Horne R, et al. Ziprasidone vs olanzapine in schizophrenia: results of a double-blind trial [poster]. American Psychiatric Association 2001 Annual Meeting; 2001 May 5–10; New Orleans (LA)

  7. Hirsch SR, Power A, Kissling W. A 28-week comparison of flexible-dose ziprasidone with haloperidol in outpatients with schizophrenia [poster]. American Psychiatric 2000 Annual Meeting; 1999 May 15–20; Washington (DC)

  8. Arató M, O’Connor R, Meltzer H, et al. Ziprasidone: efficacy in the prevention of relapse and in the long-term treatment of negative symptoms of chronic schizophrenia [abstract]. Eur Neuropsychopharmacol 1997; 7 Suppl. 2: S214

    Article  Google Scholar 

  9. Lesem MD, Zajecka JM, Swift RH, et al. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry 2001; 62 (1): 12–8

    Article  PubMed  CAS  Google Scholar 

  10. Daniel DG, Potkin SG, Reeves KR, et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing agitation associated with psychosis: a double-blind randomized trial. Psychopharmacology 2001; 155: 128–34

    Article  PubMed  CAS  Google Scholar 

  11. Pfizer. Geodon (ziprasidone HCl) prescribing information. Available from URL: http://www.pfizer.com [Accessed 2002 Dec 18]

  12. Brook S, Lucey JV, Gunn KP, et al. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. J Clin Psychiatry 2000; 61 (12): 93–41

    Article  Google Scholar 

  13. Ananth JV, Burgoyne KS, Smith MW, et al. Prolactin levels in patients taking risperidone and ziprasidone [abstract]. American Psychiatric Association 2001 Annual Meeting; 2001 May 5–10; New Orleans (LA)

  14. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686–96

    PubMed  CAS  Google Scholar 

  15. Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001 Nov; 158(11): 1774–82

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ziprasidone: zealous in the treatment of schizophrenia and schizoaffective disorder. Drugs Ther. Perspect 19, 1–4 (2003). https://doi.org/10.2165/00042310-200319040-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200319040-00001

Keywords

Search

Navigation